A5080618459- Tissue Engineering and Regenerative Medicine
- Cardiac Fibrosis and Remodeling
- Electrospun Nanofibers in Biomedical Applications
- Cardiovascular Function and Risk Factors
- Cardiac Structural Anomalies and Repair
- RNA modifications and cancer
- Bioactive Compounds in Plants
- Cardiomyopathy and Myosin Studies
- Protease and Inhibitor Mechanisms
- Kruppel-like factors research
- Potassium and Related Disorders
- Cardiac electrophysiology and arrhythmias
- Heart Failure Treatment and Management
- Heart Rate Variability and Autonomic Control
- Cardiac Ischemia and Reperfusion
- Peptidase Inhibition and Analysis
- Blood Pressure and Hypertension Studies
- RNA Research and Splicing
- Hormonal Regulation and Hypertension
- Diabetes Treatment and Management
Ruijin Hospital
2018-2023
Shanghai Jiao Tong University
2018-2023
Cardiac fibrosis has been known to play an important role in the etiology of heart failure after myocardial infarction (MI). B lymphoma Mo-MLV insertion region 1 homolog (BMI1), a transcriptional repressor, is for fibrogenesis kidneys. However, effect BMI1 on ischemia-induced cardiac remains unclear. was strongly expressed infarct wk post-MI mice and detected by Western blot histological analyses. Lentivirus-mediated overexpression significantly promoted fibrosis, worsened function 4...
Abstract The lesion core is the area with most serious injury and vigorous repair. Existing nanocarriers are difficult to break through targeted delivery for precise treatment in intracellular extracellular microenvironment. Herein, a cellular membrane‐engineered nanovesicle (CMEV) hierarchical structure constructed using double emulsion‐extrusion method by integrating neutrophil membrane, functional antibody, gelled drug‐loaded as three‐stage booster target deliver catestatin (CST), small...
Coronary artery disease (CAD) and associated comorbidities such as heart failure (HF) remain the leading cause of morbidity mortality worldwide attributed to, at least partially, lack biomarkers for efficient diagnosis. Here, we evaluated diagnostic potential serum peptidoglycan recognition protein 1 (PGLYRP1), an important component innate immunity inflammation system, both CAD HF. A machine-learning method (random forest) was used to evaluate clinical utility circulating PGLYRP1 diagnosis...
Background Catestatin has been reported as a pleiotropic cardioprotective peptide. Heart failure with preserved ejection fraction (HFpEF) was considered heterogeneous syndrome complex cause. We sought to investigate the role of catestatin in HFpEF and diastolic dysfunction. METHODS AND RESULTS Administration recombinant (1.5 mg/kg/d) improved dysfunction left ventricular chamber stiffness transverse aortic constriction mice deoxycorticosterone acetate pellet implantation, reflected by...
Abstract Myocardial fibrosis and ventricular remodeling were the key pathology factors causing undesirable consequence after myocardial infarction. However, an efficient therapeutic method remains unclear, partly due to difficulty in continuously preventing neurohormonal overactivation potential disadvantages of cell therapy for clinical practice. In this study, a rhACE2-electrospun fibrous patch with sustained releasing rhACE2 shape induction transformation niche situ was introduced,...
Background: The feasibility of spironolactone withdrawal in dilated cardiomyopathy patients with improved ejection fraction remains unknown. This study sought to determine whether can be withdrawn safely this circumstance. Methods: Consecutive idiopathic and prescribed at discharge were included prospective, observational cohort using the Risk Evaluation Management Heart Failure Trial (NCT02998788) database. Those who experienced an absolute left ventricular (LVEF) improvement ≥10% a second...
Aims: There is a high incidence of heart failure with preserved ejection fraction (HFpEF), but the options treatment are limited. A new animal model HFpEF urgently needed for in-depth research on HFpEF. Signal transducer and activator transcription 3 (STAT3) may affect passive stiffness myocardium, which determines cardiac diastolic function. We hypothesized that cardiomyocyte-specific deletion STAT3 increases stiffness, results murine features Methods Results: Cardiomyocyte-specific...
The management of blood pressure (BP) in patients with chronic heart failure (HF) is especially complex and challenging due to multiple factors involved the clinical decision making. Previous studies have demonstrated that BP associated prognosis HF patients. However, current guidelines for or hypertension haven′t yet provided definite evidence-based recommendations target Recently, some studys explored application ambulatory monitoring HF. Here we reviewed progress from following aspects,...